Delivery Order SPE2DB20D3303-SPE2DB25FA2MB
- Not listed
- The Defense Logistics Agency awarded a $4,152.30 delivery order to AmerisourceBergen Drug Corp for Tresiba FlexTouch 200 Unit/ML 3ML insulin pens on July 21, 2025, with completion scheduled for July 22, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a $4,222.74 delivery order to AmerisourceBergen Drug Corp for Tresiba FlexTouch 200 unit/ml insulin pens (3ml). This contract, awarded on July 21, 2025, represents a firm fixed-price procurement with an ultimate completion date of July 22, 2025. The award was not set-aside and was competitively awarded through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Tresiba FlexTouch 100 unit/mL insulin pens in 3mL quantities. This $2,146.80 firm fixed-price delivery order, with an ultimate completion date of August 1, 2025, represents a non-set-aside competitive award supporting federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $3,737.07 to AmerisourceBergen Drug Corp for Tresiba FlexTouch 200 unit/mL 3mL insulin pens on August 12, 2025, with an ultimate completion date of August 13, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Tresiba FlexTouch 100 Unit/ML 3ML insulin pens, with a ceiling value of $1,384.20. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of July 24, 2025, and performance based in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's critical role as a pharmaceutical supplier to the federal government,...
- The Defense Logistics Agency awarded a $4,982.76 delivery order to AmerisourceBergen Drug Corp for TRESIBA FLEXTOUCH 200 Unit/ML 3ML insulin pens, with an ultimate completion date of July 23, 2025. This non-set-aside contract utilizes a firm fixed-price arrangement and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Tresiba FlexTouch 100 Unit/mL 3mL insulin pens, with a ceiling value of $1,582.33 and a firm fixed price structure. The contract was awarded on July 21, 2025, with an ultimate completion date of July 22, 2025, and represents a non-competitive, non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a firm fixed price delivery order contract for $2,001.55 to supply Tresiba Flextouch 200 unit/mL 3mL insulin pens. This delivery order was issued under an existing indefinite delivery contract (IDC) between DLA and Amerisourcebergen Drug Corp, which has a potential value of up to $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the...
- The Defense Logistics Agency awarded a delivery order valued at $2,768.40 to AmerisourceBergen Drug Corp for Tresiba FlexTouch 100 Unit/mL 3mL insulin pens. This is a firm fixed-price, competitively awarded delivery order with an ultimate completion date of July 23, 2025. The product will be delivered to the company's headquarters location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- This federal contract award is for the delivery of Tresiba FlexTouch insulin pens, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The $2,484.90 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on November 27, 2024, with a completion date of November 29, 2024. The contract is not designated as a set-aside and represents a direct procurement under AmerisourceBergen's existing Indefinite Delivery Contract...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA2MBDelivery Order
The Defense Logistics Agency awarded a $1,384.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tresiba FlexTouch 100 Unit/ML 3ML insulin pens. This is a non-set-aside contract with an ultimate completion date of August 13, 2025, and performance will occur at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement supporting military and veteran healthcare systems. The Tresiba insulin supply fulfills the Department of Defense's ongoing need for diabetes management medications across military healthcare programs. This award reflects AmerisourceBergen's competitive position and capability to efficiently deliver specialized pharmaceutical products through the DLA Medical Supply Chain, which the company supports through a comprehensive portfolio of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 8/12/25 |